- Nuclear reactors, which, as ANSTO, generate 177 ‑ Lutetium, are few in the world - only about five. It is good that we have a local source of Lutetia and the competences for the production of the drug in the hospital. The final product does not come to us in a beautiful box. But not for all such a path is possible. In the future, the drug will be manufactured in batches and shipped around the world. Lutetia has a half-life of seven days, so the drug can be delivered safely. I think in five years it will be possible to buy it anywhere.
- When your treatment is confirmed and approved, will compulsory health insurance cover it in Australia?
- In fact, the treatment is not so expensive. We are talking about the exact number of cycles: diagnosis + therapy. In total, this is 4-6 doses of Lutetia, which is cheaper than chemotherapy. While I do not have exact figures, but I do not expect that our treatment method will be more expensive than the existing ones, rather, it will turn out to be cheaper. I know that in some countries, for example, in India and South Africa, such treatment is already available on a paid basis, and it is cheaper than chemotherapy. Therefore, patients even at earlier stages tend to complete the course in order to save money. In other countries, the situation, of course, may be quite different.
- How in the scientific world relate to the practice of India and South Africa? They are already selling the service, while others are just testing.
“I think that in order to make treatment accessible, we need approval from our fellow oncologists and other specialists. Without evidence that convincingly demonstrates that therapy works and is better than existing practices, they will not recommend such treatment to patients. What our oncologists need now is evidence from randomized clinical trials. Without the results of such tests to replicate the method of treatment will not work, it will remain niche. Patients will search for information on the Internet, then fly to some center in India. But it should be available to everyone, not just in one or two centers. And theranostics of prostate cancer has every chance.